TY  - JOUR
AU  - Đurasinović, Vladislava T.
AU  - Mihaljević, Biljana
AU  - Šipetić-Grujičić, Sandra B.
AU  - Ignjatović, Svetlana
AU  - Trajković, Goran
AU  - Todorović-Balint, Milena R.
AU  - Antić, Darko
AU  - Bila, Jelena S.
AU  - Anđelić, Bosko M.
AU  - Jelicić, Jelena J.
AU  - Vuković, Vojin M.
AU  - Nikolić, Aleksandra M.
AU  - Klek, Stanislaw
PY  - 2018
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/3236
AB  - Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency  lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D  lt  19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D  lt  19.6 nmol/l had a significantly shorter PFS.
PB  - Springer, New York
T2  - Synthetic Communications
T1  - 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?
VL  - 26
IS  - 8
SP  - 2825
EP  - 2832
DO  - 10.1007/s00520-018-4101-9
ER  - 

@article{
author = "Đurasinović, Vladislava T. and Mihaljević, Biljana and Šipetić-Grujičić, Sandra B. and Ignjatović, Svetlana and Trajković, Goran and Todorović-Balint, Milena R. and Antić, Darko and Bila, Jelena S. and Anđelić, Bosko M. and Jelicić, Jelena J. and Vuković, Vojin M. and Nikolić, Aleksandra M. and Klek, Stanislaw",
year = "2018",
abstract = "Introduction Vitamin D has a role in cellular differentiation, proliferation, apoptosis, and angiogenesis and therefore is studied as a prognostic factor in cancer. The aim of our study was to assess the prevalence and significance of 25(OH)D deficiency in patients with lymphoid malignancies. Methodology Between January 2014 and June 2016 at the Clinic for Hematology, Clinical Center of Serbia, Belgrade, the pretreatment serum level of 25(OH)D was determined in 133 (62 women/71 men, median age 58 (18-84) years) previously untreated patients with lymphoid malignancy using a chemiluminescent immunoassay. From their medical records, we noted the age, clinical stage, Eastern Cooperative Oncology Group Performance Scale (ECOG PS), nutritional status using the Nutritional Risk Score 2002 (NRS2002), the time of year, comorbidity index, progression, and progression-free survival (PFS) for a median of 20 (1-32) months. The optimal cutoff point for prediction of outcome was determined using the Maximally Selected Rank Statistics. Results There were 37 (27.8%) patients with the severe 25(OH)D deficiency  lt = 25 nmol/l, 80 (60.2%) with 25(OH)D deficiency 25-50 nmol/l, and 16 (12%) with 25(OH)D insufficiency 50-75 nmol/l. None of the patients had the desired normal level. There were significant differences between groups in regard to ECOG PS, NRS2002, type of lymphoma, and progression. The severely 25(OH)D-deficient patients had a shorter mean time until progression (P = 0.018). Cox regression analysis showed that 25(OH)D  lt  19.6 nmol/l remained the only significant parameter for PFS (HR = 2.921; 95% CI 1.307-6.529). Conclusion The prevalence of 25(OH)D deficiency in the analyzed group of patients with lymphoid malignancies is high and greater in malnourished individuals. Patients with pretreatment serum 25(OH)D  lt  19.6 nmol/l had a significantly shorter PFS.",
publisher = "Springer, New York",
journal = "Synthetic Communications",
title = "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?",
volume = "26",
number = "8",
pages = "2825-2832",
doi = "10.1007/s00520-018-4101-9"
}

Đurasinović, V. T., Mihaljević, B., Šipetić-Grujičić, S. B., Ignjatović, S., Trajković, G., Todorović-Balint, M. R., Antić, D., Bila, J. S., Anđelić, B. M., Jelicić, J. J., Vuković, V. M., Nikolić, A. M.,& Klek, S.. (2018). 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. in Synthetic Communications
Springer, New York., 26(8), 2825-2832.
https://doi.org/10.1007/s00520-018-4101-9

Đurasinović VT, Mihaljević B, Šipetić-Grujičić SB, Ignjatović S, Trajković G, Todorović-Balint MR, Antić D, Bila JS, Anđelić BM, Jelicić JJ, Vuković VM, Nikolić AM, Klek S. 25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?. in Synthetic Communications. 2018;26(8):2825-2832.
doi:10.1007/s00520-018-4101-9 .

Đurasinović, Vladislava T., Mihaljević, Biljana, Šipetić-Grujičić, Sandra B., Ignjatović, Svetlana, Trajković, Goran, Todorović-Balint, Milena R., Antić, Darko, Bila, Jelena S., Anđelić, Bosko M., Jelicić, Jelena J., Vuković, Vojin M., Nikolić, Aleksandra M., Klek, Stanislaw, "25(OH) vitamin D deficiency in lymphoid malignancies, its prevalence and significance. Are we fully aware of it?" in Synthetic Communications, 26, no. 8 (2018):2825-2832,
https://doi.org/10.1007/s00520-018-4101-9 . .

TY  - JOUR
AU  - Vucelić, Dragica
AU  - Jesić, Rada
AU  - Jovičić, Snežana
AU  - Zivotić, Maja
AU  - Grubor, Nikica
AU  - Trajković, Goran
AU  - Canić, Ivana
AU  - Elezović, Ivo
AU  - Antović, Aleksandra
PY  - 2015
UR  - https://farfar.pharmacy.bg.ac.rs/handle/123456789/2396
AB  - Background: The Clauss fibrinogen method and thrombin clotting time (TCT) are still routinely used in patients with cirrhosis to define fibrinogen concentration and clotting potential. The thromboelastometric functional fibrinogen FIBTEM assay evaluates the strength of fibrin-based clots in whole blood, providing information on both quantitative deficit and fibrin polymerization disorders. Objective: To compare these three methods of assessing fibrinogen in patients with cirrhosis of different aetiologies, characterized by impairment in fibrinogen concentration as well as functional aberrance. Methods: Sixty patients with alcoholic and 24 patients with cholestatic cirrhosis were included (Child-Pugh score (CPs) A, n = 24; B, n = 32; C, n = 28). All parameters were compared with those from a control group. Maximum clot firmness (MCF) in the FIBTEM test was assessed in regard to its relevance in detection of qualitative fibrinogen disorders in comparison with results obtained by standard measurement methods, i.e. the Clauss fibrinogen method and TCT. Results: With increased cirrhosis severity, fibrinogen and FIBTEM-MCF levels significantly declined (p = 0.002), while TCT was significantly prolonged (p = 0.002). In all CPs groups, fibrinogen strongly correlated with FIBTEM-MCF (r = 0.77, r = 0.72, r = 0.74; p  lt  0.001), while cross-correlations of other assays were highly variable. The prevalence of decreased FIBTEM-MCF values ( lt 9 mm) was significantly higher in advanced CPs categories (p = 0.027), whereby the highest prevalence was detected in patients with CPsC (10/16; 62.5%). Nine of the 16 patients with decreased FIBTEM-MCF values had also decreased fibrinogen levels, while in the remaining 7 patients fibrinogen levels were within the reference range, indicating the possible presence of qualitatively altered fibrinogen that could be detected by FIBTEM-MCF. Conclusions: FIBTEM-MCF may be considered as a reliable alternative to standard plasma fibrinogen measurement in cirrhotic patients, especially in evaluating fibrin polymerization disorders in these patients. Further studies are needed to evaluate the usefulness of this assay in predicting bleeding complications in cirrhotic patients as well as monitoring replacement treatment.
PB  - Pergamon-Elsevier Science Ltd, Oxford
T2  - Tohoku Journal of Experimental Medicine
T1  - Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis
VL  - 135
IS  - 6
SP  - 1124
EP  - 1130
DO  - 10.1016/j.thromres.2015.04.003
ER  - 

@article{
author = "Vucelić, Dragica and Jesić, Rada and Jovičić, Snežana and Zivotić, Maja and Grubor, Nikica and Trajković, Goran and Canić, Ivana and Elezović, Ivo and Antović, Aleksandra",
year = "2015",
abstract = "Background: The Clauss fibrinogen method and thrombin clotting time (TCT) are still routinely used in patients with cirrhosis to define fibrinogen concentration and clotting potential. The thromboelastometric functional fibrinogen FIBTEM assay evaluates the strength of fibrin-based clots in whole blood, providing information on both quantitative deficit and fibrin polymerization disorders. Objective: To compare these three methods of assessing fibrinogen in patients with cirrhosis of different aetiologies, characterized by impairment in fibrinogen concentration as well as functional aberrance. Methods: Sixty patients with alcoholic and 24 patients with cholestatic cirrhosis were included (Child-Pugh score (CPs) A, n = 24; B, n = 32; C, n = 28). All parameters were compared with those from a control group. Maximum clot firmness (MCF) in the FIBTEM test was assessed in regard to its relevance in detection of qualitative fibrinogen disorders in comparison with results obtained by standard measurement methods, i.e. the Clauss fibrinogen method and TCT. Results: With increased cirrhosis severity, fibrinogen and FIBTEM-MCF levels significantly declined (p = 0.002), while TCT was significantly prolonged (p = 0.002). In all CPs groups, fibrinogen strongly correlated with FIBTEM-MCF (r = 0.77, r = 0.72, r = 0.74; p  lt  0.001), while cross-correlations of other assays were highly variable. The prevalence of decreased FIBTEM-MCF values ( lt 9 mm) was significantly higher in advanced CPs categories (p = 0.027), whereby the highest prevalence was detected in patients with CPsC (10/16; 62.5%). Nine of the 16 patients with decreased FIBTEM-MCF values had also decreased fibrinogen levels, while in the remaining 7 patients fibrinogen levels were within the reference range, indicating the possible presence of qualitatively altered fibrinogen that could be detected by FIBTEM-MCF. Conclusions: FIBTEM-MCF may be considered as a reliable alternative to standard plasma fibrinogen measurement in cirrhotic patients, especially in evaluating fibrin polymerization disorders in these patients. Further studies are needed to evaluate the usefulness of this assay in predicting bleeding complications in cirrhotic patients as well as monitoring replacement treatment.",
publisher = "Pergamon-Elsevier Science Ltd, Oxford",
journal = "Tohoku Journal of Experimental Medicine",
title = "Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis",
volume = "135",
number = "6",
pages = "1124-1130",
doi = "10.1016/j.thromres.2015.04.003"
}

Vucelić, D., Jesić, R., Jovičić, S., Zivotić, M., Grubor, N., Trajković, G., Canić, I., Elezović, I.,& Antović, A.. (2015). Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis. in Tohoku Journal of Experimental Medicine
Pergamon-Elsevier Science Ltd, Oxford., 135(6), 1124-1130.
https://doi.org/10.1016/j.thromres.2015.04.003

Vucelić D, Jesić R, Jovičić S, Zivotić M, Grubor N, Trajković G, Canić I, Elezović I, Antović A. Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis. in Tohoku Journal of Experimental Medicine. 2015;135(6):1124-1130.
doi:10.1016/j.thromres.2015.04.003 .

Vucelić, Dragica, Jesić, Rada, Jovičić, Snežana, Zivotić, Maja, Grubor, Nikica, Trajković, Goran, Canić, Ivana, Elezović, Ivo, Antović, Aleksandra, "Comparison of standard fibrinogen measurement methods with fibrin clot firmness assessed by thromboelastometry in patients with cirrhosis" in Tohoku Journal of Experimental Medicine, 135, no. 6 (2015):1124-1130,
https://doi.org/10.1016/j.thromres.2015.04.003 . .